Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Update

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 104,400 shares, a decline of 51.4% from the December 15th total of 214,800 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average daily volume of 275,500 shares, the short-interest ratio is currently 0.4 days.

Entero Therapeutics Price Performance

Shares of NASDAQ:ENTO traded up $0.02 during trading on Tuesday, hitting $0.56. 21,533 shares of the stock were exchanged, compared to its average volume of 58,617. The company’s fifty day simple moving average is $0.58 and its 200-day simple moving average is $0.59. Entero Therapeutics has a 1-year low of $0.19 and a 1-year high of $9.35.

Entero Therapeutics (NASDAQ:ENTO) last announced its earnings results on Monday, October 21st. The company reported ($3.37) EPS for the quarter. Sell-side analysts predict that Entero Therapeutics will post -1.13 earnings per share for the current year.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.